At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Doxorubicin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer
In Brief
A clinical study evaluating Doxorubicin, Cyclophosphamide, and 2 other interventions for Breast Cancer. Completed, enrolled 45 participants across 8 sites.
Detailed Summary
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard chemotherapy in the treatment of early stage node positive or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for patients, this would provide rationale for further studies in a larger randomized fashion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBayer
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedOct 2007
Primary CompletionJan 2008
Study CompletionApr 2011
TodayJul 2026
First PostedOct 16, 2007
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2008
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.7 years ago
Interventions
Doxorubicindrug
Cyclophosphamidedrug
Paclitaxeldrug
Sorafenibdrug